Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,549 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00751205 | Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC) | completed | Phase 2 | 150 | BayerINDUSTRY | 6 | Oct 28, 2014 | clinicaltrials |
| NCT00928642 | Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer | completed | Phase 2 | 8 | Henry M. Jackson Foundation for the Advancement of Military MedicineOTHER | 1 | Oct 21, 2014 | clinicaltrials |
| NCT00407485 | VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2014 | clinicaltrials |
| NCT00868192 | Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma | completed | Phase 2 | 38 | Washington University School of MedicineOTHER | 1 | Oct 20, 2014 | clinicaltrials |
| NCT00886873 | Mifepristone 10 or 5 mg for 6 Months to Treat Uterine Fibroids(Mifemyo_2) | completed | Phase 2 / Phase 3 | 100 | Mediterranea Medica S. L.OTHER | 1 | Oct 17, 2014 | clinicaltrials |
| NCT00683475 | A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer | completed | Phase 2 | 138 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 16, 2014 | clinicaltrials |
| NCT01009736 | Effects of Tomato-Soy Juice on Biomarkers in Patients With Prostate Cancer Undergoing Prostatectomy | completed | Phase 1 / Phase 2 | 60 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Oct 16, 2014 | clinicaltrials |
| NCT01481701 | A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma | completed | Phase 2 | 90 | Jules Bordet InstituteOTHER | 1 | Oct 15, 2014 | clinicaltrials |
| NCT01834469 | Imaging of Peritoneal Carcinomatosis From Ovarian Carcinoma Patients(OV-AP-ICG-IV) | completed | Phase 1 / Phase 2 | 10 | Jules Bordet InstituteOTHER | 1 | Oct 15, 2014 | clinicaltrials |
| NCT00520403 | A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer. | completed | Phase 2 | 25 | Hoffmann-La RocheINDUSTRY | 1 | Oct 13, 2014 | clinicaltrials |
| NCT00103194 | Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer | completed | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2014 | clinicaltrials |
| NCT00477386 | Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 28 | Indiana UniversityOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT00570882 | Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC) | completed | Phase 2 | 76 | Asan Medical CenterOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT01490437 | Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma(PECULIAR) | completed | Phase 2 | 42 | Asan Medical CenterOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT01451424 | Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids | completed | Phase 2 | 40 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 29, 2014 | clinicaltrials |
| NCT00323882 | Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer | completed | Phase 1 / Phase 2 | 75 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 28, 2014 | clinicaltrials |
| NCT01104675 | Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer | completed | Phase 2 | 64 | CASI pharmaceuticals, Inc.INDUSTRY | 2 | Aug 6, 2014 | clinicaltrials |
| NCT00476645 | Fulvestrant in Hormone Refractory Prostate Cancer | completed | Phase 2 | 10 | Stanford UniversityOTHER | 1 | Aug 5, 2014 | clinicaltrials |
| NCT00672594 | Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy | completed | Phase 2 | 30 | Duke UniversityOTHER | 1 | Aug 4, 2014 | clinicaltrials |
| NCT00548418 | Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer | completed | Phase 2 | 27 | Washington University School of MedicineOTHER | 1 | Aug 1, 2014 | clinicaltrials |
| NCT01424930 | A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 25 | Janssen-Ortho Inc., CanadaINDUSTRY | 1 | Jul 25, 2014 | clinicaltrials |
| NCT00866320 | Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab | completed | Phase 2 | 49 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 23, 2014 | clinicaltrials |
| NCT00349557 | Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer | completed | Phase 2 | 18 | Benaroya Research InstituteOTHER | 1 | Jul 16, 2014 | clinicaltrials |
| NCT01408004 | Rotating Pazopanib and Everolimus to Avoid Resistance(ROPETAR) | completed | Phase 2 | 101 | Netherlands Working Group on Immunotherapy of OncologyOTHER | 1 | Jul 16, 2014 | clinicaltrials |
| NCT00278993 | Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy | completed | Phase 2 | 108 | Eisai Inc.INDUSTRY | 1 | Jul 14, 2014 | clinicaltrials |
| NCT00882258 | Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids | completed | Phase 2 | 144 | Repros Therapeutics Inc.INDUSTRY | 1 | Jul 8, 2014 | clinicaltrials |
| NCT00265135 | A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 68 | Centocor, Inc.INDUSTRY | 4 | Jul 3, 2014 | clinicaltrials |
| NCT00515073 | Papillary Serous Carcinoma of the Endometrium | completed | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 3, 2014 | clinicaltrials |
| NCT00919035 | Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients | completed | Phase 2 | 21 | Oncology Specialists, S.C.OTHER | 1 | Jun 30, 2014 | clinicaltrials |
| NCT00459654 | A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer | completed | Phase 2 | 64 | BayerINDUSTRY | 2 | Jun 25, 2014 | clinicaltrials |
| NCT00337077 | Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | completed | Phase 2 | 121 | National Cancer Institute (NCI)NIH | 1 | Jun 23, 2014 | clinicaltrials |
| NCT00515697 | A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 39 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 18, 2014 | clinicaltrials |
| NCT01163552 | Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity | completed | Phase 2 | 5 | St. Luke's-Roosevelt Hospital CenterOTHER | 1 | Jun 13, 2014 | clinicaltrials |
| NCT00101348 | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2014 | clinicaltrials |
| NCT00918281 | Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection | completed | Phase 2 | 70 | GE HealthcareINDUSTRY | 1 | Jun 9, 2014 | clinicaltrials |
| NCT00471536 | Pazopanib in Treating Patients With Metastatic Urothelial Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 3 | May 30, 2014 | clinicaltrials |
| NCT00054639 | Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma | completed | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00390468 | Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00330161 | Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer | completed | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | May 26, 2014 | clinicaltrials |
| NCT00245102 | Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma | completed | Phase 2 | 147 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00003449 | Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer | completed | Phase 2 | 35 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00183794 | Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma | completed | Phase 2 | 20 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00183924 | Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy. | completed | Phase 2 | 20 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00083122 | Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | May 21, 2014 | clinicaltrials |
| NCT00093496 | Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer | completed | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | May 20, 2014 | clinicaltrials |
| NCT00176605 | Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer | completed | Phase 2 | 15 | Rutgers, The State University of New JerseyOTHER | 1 | May 20, 2014 | clinicaltrials |
| NCT00081614 | A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma | completed | Phase 2 | 100 | Genentech, Inc.INDUSTRY | 1 | May 16, 2014 | clinicaltrials |
| NCT01088529 | Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer | completed | Phase 2 | 66 | Cougar Biotechnology, Inc.INDUSTRY | 1 | May 15, 2014 | clinicaltrials |
| NCT01711112 | Salvage Docetaxel for Pretreated Urothelial Cancer | completed | Phase 2 | 31 | Samsung Medical CenterOTHER | 1 | May 15, 2014 | clinicaltrials |
| NCT00126542 | Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 14, 2014 | clinicaltrials |
Data updated 24 days agoSource updated Oct 28, 2014source: clinicaltrials